BioSight
Companies
OnKure Therapeutics, Inc. logo

OKUR

NASDAQBOULDER, CO
OnKure Therapeutics, Inc.

OnKure Therapeutics is a clinical-stage biotech company developing small-molecule drug candidates, with OKI-219 as its lead program. OKI-219 is being evaluated as a potential treatment in combination with other drugs, and the company is also exploring PI3K inhibitors as a therapeutic approach. OnKure is currently conducting preclinical and clinical studies to advance its pipeline, though it remains dependent on obtaining additional funding to complete development and pursue regulatory approval.

Price history not yet available for OKUR.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar